Recon: FTC warns drugmakers over ‘junk’ Orange Book patents; FDA solicits public feedback on advisory committee reforms

• FTC issues warnings on ‘junk’ patent listings for Ozempic and other drugs (STAT)
• Creating the next wave of antibody therapies requires innovative collaboration (STAT)
• FDA wants to hear your thoughts on advisory committees (STAT)
• US FDA grants full approval for Pfizer's cervical cancer drug (Reuters)
• Weight-loss drug drives Eli Lilly to raise 2024 sales forecast by $2 billion (Reuters) (Endpoints)
• FDA asks for public input on advisory committee reforms (Endpoints)
• US FDA Adcomm Reform: Does Listening Session Suggest No Major Near-Term Changes? (Pink Sheet)
• Lilly scraps trials of Verzenio, Jardiance and a gene therapy from Prevail (Endpoints)
• Sandoz reaches agreement with Amgen over patent dispute (Reuters)
• Walmart exits live and virtual care business, five years after push into care delivery (Endpoints)
• Bristol Myers, Johnson & Johnson plot appeal after US judge dismisses IRA lawsuits (Fierce Pharma)

• Bird flu may infect cows outside the US, says WHO (Reuters)
• GE HealthCare misses quarterly revenue estimates on weakness in China market (Reuters)
• Australian regulator examines possible contamination of Indian spice mixes (Reuters)
• EU Launches Critical Medicines Alliance But Prospect Of Act On Manufacturing Still Uncertain (Pink Sheet)
• ‘Shocking’ MHRA Performance & Poor Data Transparency Blamed For UK’s Clinical Trial Crisis (Pink Sheet)
• MHRA Needs ‘Rebuilding’ After Post-Brexit Loss Of Capacity And Industry Investment (Pink Sheet)

• New, serious safety risk related to MorphoSys’ cancer drug complicates, potentially threatens, Novartis acquisition (STAT)
• Akili to lay off 46% of its staff, explore strategic options amid sluggish sales (STAT)
• Annovis tumbles as Alzheimer's treatment misses in mid-stage study (Reuters)
• One dose of Novo Nordisk's Wegovy back in supply, FDA website shows (Reuters)
• Harmony Biosciences buys small epilepsy biotech for $35M, plus milestones (Endpoints)
• Daré's royalty deal; Qlaris Bio raises $24M (Endpoints)
• Real Chemistry debuts a one-stop dashboard for all things GLP-1 (Endpoints)
• In one of JP Morgan's first biotech bets, Enlaza raises $100M for its permanently binding protein drugs (Endpoints)
• US FDA’s Vaccine Office Emerges From Non-COVID-19 Backlog (Pink Sheet)

• With younger women getting breast cancer, national panel lowers mammogram screening age to 40 (STAT)
• Abbott Receives FDA Approval For Esprit BTK Drug-Eluting Resorbable Scaffold (MedTech Insight)
• It’s Official: FDA Drops Final Rule On LDTs (MedTech Insight)
• FDA defends LDT final rule, while critics fear it upends lab industry (MedTech Dive)
• Hologic to buy Endomagnetics for $310M (MedTech Dive)

• Pfizer to pay $25.5 mln to settle remaining Effexor XR antitrust claims (Reuters)
• AI is becoming the exclusive province of academic medicine. A new initiative aims to change that (STAT)
• Biden cybersecurity plan for hospitals entails carrots first, then sticks, health official says (STAT)
• Protect the health of pregnant people and their children by including them in research (STAT)
• UnitedHealth CEO reveals cyberattack origins ahead of Change Healthcare hearings (Endpoints)
• Florida abortion clinics and funds face uncertain future on eve of six-week ban (Reuters)